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KEY POINTS
 Romidepsin and vorinostat are the only histone deacetylase (HDAC) inhibitors currently approved
for cutaneous T-cell lymphomas (CTCL), and belinostat is also approved for peripheral T-cell
lymphoma.
 There is little information regarding combinations of HDAC inhibitors with other CTCL therapies.
There are no data to exclude combining HDAC inhibitors with skin-directed therapies.
 Although there are now several approved treatments available, the field is still in need of newer
drugs and approaches for this disease with poor prognosis.INTRODUCTION
Cutaneous T-cell lymphomas (CTCLs) are non-
Hodgkin’s T-cell lymphomas that present as skin
lesions. The most common is mycosis fungoides
(MF) and its leukemic variant, Se´zary syndrome
(SS). CTCLs are currently rarely cured and may
have an indolent clinical course. MF with large
cell transformation, defined as greater than 25%
atypical lymphocytes with nuclei 4 times the
normal size, has poor survival, similar to that of pe-
ripheral T-cell lymphoma (PTCL) with a 5-year
overall survival of only 32% with involved skin
and 7% with extracutaneous involvement.1 The
failure of MF with large cell transformation and
PTCL to respond to multiagent chemotherapy
with cytoxan, adriamycin, oncovin, and predni-
sone (CHOP) or CHOP-based chemotherapy has
resulted in a search for novel targeted agents
including antibodies and gene modulators. His-
tone deacetylase (HDAC) inhibitors are small mol-
ecules that seem to be particularly active for T-cell
lymphoma.2Division of Internal Medicine, Department of Dermatolo
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DEACETYLASE INHIBITORS
Histone acetyltransferases and HDACs are en-
zymes capable of modifying histone and nonhis-
tone acetylation sites in proteins. Histone
acetyltransferases and HDACs regulate a broad
range of pathways and processes that are dysre-
gulated in cancer, including the cell cycle,
apoptosis, and protein folding. The balance be-
tween histone acetylation effected by acetylases
and deacetylation is mediated by HDAC inhibitors
and is abnormal in cancer cells.3,4 Acetylation of
histones promotes opened chromatin, transcrip-
tion factor binding to promoters, and initiation of
mRNA synthesis encoding genes.5 The action of
deacetylase inhibitors is not limited to histones
and can prevent deacetylation of other proteins,
such as the tumor promoter p53.
HDAC inhibitors are small molecules that
interact with HDAC’s catalytic sites preventing
the removal of acetyl groups, counteracting the ef-
fects of HDACs. Valproic acid was the first HDACgy, University of Texas MD Anderson Cancer Center,
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Duvic758inhibitor investigated for malignancy followed by
development of pan-HDAC and more selective in-
hibitors to improve efficacy and safety. Whether
HDAC inhibitors with selected specificity are
more effective with fewer side effects and thus
are superior to pan-inhibitors is still under debate.6
Wells and colleagues6 showed that selective
HDAC3 inhibition by the first HDAC3 inhibitor,
RGFP966, resulted in decreased cell growth in
CTCL lines owing to increased apoptosis associ-
ated with DNA damage and impaired S phase pro-
gression. HDAC3 was present around the DNA
replication forks and significantly decreased the
speed of replication.
The 18 known HDACs are classified into 4 main
groups based on their homology to yeast HDACs
and dependence on the essential cofactor, zinc,
present at the active sites. Zinc-dependent
HDACs include those of class I that target histones
and includes HDACs 1, 2, 3, and 8; class IIa
HDACs that target both histones and nonhistone
proteins and includes HDACs 4, 5, 7, 9; Class IIb
HDAC 6, which targets the mitogen-activated pro-
tein kinase pathway,7 and 10; and class IV HDAC
targeting only HDAC 11. The class 3 HDACs,
called sirtulins (1–7), are zinc independent and
nicotinamide adenine dinucleotide dependent.5,8
HDAC inhibitors have been classified by 4 major
chemical structures and their ability to interact with
specific HDACs. By clinical structure, HDAC
inhibitors are short-chain fatty acids (valproic
acid), hydroxamic acids (vorinostat [suberoylani-
lide hydroxamic acid (SAHA)], panobinostat
[LBH589], and quisinostat [JNJ-26481585]), dep-
sipeptide (romidepsin [FK228]), and benzamides
(entinostat [MS-275] and mocetinostat [MGCD-
0103]). The chemical structures of the hydroxamic
acids and romidepsin are shown in Fig. 1. Vorino-
stat was the first HDAC inhibitor approved by US
Food and Drug Administration (FDA) for use in can-
cer based on 2 phase II studies in refractory CTCL
patients.9,10 In a study of 45 PTCL patients, HDAC
1, 2, and 6 were overexpressed compared with
normal lymphoid tissue making T-cell lymphoma
a logical target for HDAC inhibition.11
HDAC inhibitors inhibit cell cycle progression by
upregulating p21, p27, and p16, which bind to and
deactivate CDK2 and CDK4 leading to G1 arrest.12
HDAC inhibitors may also inhibit S-phase progres-
sion through inhibition of cytidine triphosphate syn-
thase and thymidylate synthetase, involved in DNA
synthesis.13 They also induce generation of reac-
tive oxygen species while inhibiting DNA repair.6
The balance between proapoptotic and antia-
poptotic factors is influenced by HDAC inhibitors.
HDAC inhibitors increase expression of genes en-
coding death receptors and their respectiveligands (Fas and Apo 2 L/TRAIL receptors, DR4
and DR5). They also downregulate c-FLIP (a nega-
tive regulator of caspase-8), and modulate the
mitogen-activated protein kinase pathway, a
possible mechanism of resistance.12–14 HDAC in-
hibitors also upregulate expression of proapoptic
BH3 domain proteins while downregulating the
antiapoptotic proteins BCL-2, BCL-XL, and
MCL-1.12 In leukemia cells, apoptosis-involved
pathways independent of p53, regulated by Bcl-
2/Bxl-XL, c-Jun, and p21CIP1.15
The STAT family of transcription factors (STAT-3,
-4, -5, and -6) are thought tohaveakey role indriving
T-cell proliferation in CTCL.16 STAT-4, associated
with a T helper cell (Th) 1 phenotype, is downregu-
lated in CTCL cell lines, whereas STAT-6, which is
associated with Th2 phenotype, is upregulated.
Change in STAT expression could contribute to the
TH1 to TH2 phenotype switch seen in disease pro-
gression. Increasing STAT-5 signaling may upregu-
late Th2 cytokines and synergize to promote the
malignancy. Downregulation of STAT-4 may be
owing to upregulation of STAT 5 signaling during
the early stages of CTCL. HDAC inhibitors may act
through STATs to increase the Th1>TH2 response.
Growing evidence shows that STAT5 is impor-
tant for the expression of anti-apoptotic proteins
(including bcl-2 and bcl-x), cell cycle genes (Cyclin
D and c-myc), and the oncogenic miR-155 micro-
RNA (which has a putative binding site on the
STAT4 30UTR). Evidence suggests that with
STAT5 upregulation early in CTCL, the resulting
miR-155 increase promotes proliferation of malig-
nant T-cells and may be responsible for STAT-4
decline and conversion to TH2 phenotype.16,17
The imbalance between STAT-4 and STAT-6 is
thought tobeowing toaberrant histone acetylation.
MyLa cells treated with romidepsin or vorinostat,
show downregulation of STAT-6 and upregulation
of STAT-4, which is beneficial for CTCL. HDAC in-
hibitors may restore this balance because treat-
ment with HDAC inhibitors have been shown to
upregulate STAT-4 and decrease STAT-6 in vitro.16VORINOSTAT (ZOLINZA; SUBEROYLANILIDE
HYDROXAMIC ACID)
The mechanisms of action of vorinostat have been
studied extensively with complexity related to the
ability of HDAC inhibitors to modulate multiple
genes and cell types.3 Vorinostat induces differen-
tiation and growth arrest in a wide range of cancer
cells studied.18,19
We reported that CTLC lines treated in vitro
with vorinostat underwent apoptosis selectively
compared with normal T cells.9 The level of acety-
lated histone protein does not predict response,
Fig. 1. Chemical structures of histone deacetylase inhibitors.
HDAC-Inhibitors for CTCL 759but did increase in duration with higher doses of
vorinostat. In MF skin lesions, phospho-stat 3
localized in the cytoplasm at baseline became nu-
clear in distribution in patients who had clinical re-
sponses to vorinostat.9 Vorinostat and romidepsin
were reported to downregulate expression of
interleukin-10 (a Th2 cytokine) in CTCL cells.20
Vorinostat (suberoyl 1 anilide 1 hydroxamic
acid or SAHA),21 is a class I/II HDAC inhibitor
with a hydroxamic structure. After activity wasshown in cancer cell lines,18 vorinostat was evalu-
ated in phase I trials as both an oral and intrave-
nous formulation with initial responses seen in
hematopoietic malignancies, including T-cell lym-
phoma.19 Vorinostat was the first HDAC inhibitor
to receive FDA approval in 2006 for the treatment
of relapsed/refractory CTCL.22 Approval was
based on the overall response seen in 2 phase II
single-arm clinical trials.23,24 A phase I study was
also completed in patients with advanced
Duvic760leukemia,25 and the drug was active in nodal
lymphoma.19
The initial phase II trial was a single-center,
open-label, dose-ranging study of 33 advanced
CTCL patients, all with either MF or SS. Patients
with relapsed/refractory MF/SS and a median of
5 prior therapies were included. Response to vor-
inostat in the first group of patients suggested that
an optimal dose of 400 mg given orally once daily9
and an overall response rate (ORR) of 24% with no
complete remissions (CR). The median duration of
response was only about 4 months.9 Intermittent
dose schedules of 300 mg by mouth twice daily
for 2 weeks with a 2 week rest were also clinically
active, especially for SS patients, but the highest
dose was associated with more frequent and se-
vere dose-limiting thrombocytopenia.9 The most
common drug-related adverse events (AEs) were
fatigue (73%), thrombocytopenia (54%), diarrhea
(49%), nausea (49%), and dysgeusia (46%); the
most common grade 3 or 4 AE was thrombocyto-
penia (19%), followed by anemia, deep vein
thrombosis, dehydration, and pyrexia (each expe-
rienced by 8% of patients).
The second phase II multicenter, open-label,
clinical trial enrolled 74 patients with MF/SS who
had at least 2 prior systemic therapies. The ORR
of 29% was similar to the first study and the me-
dian duration of response was longer than
6 months. Of note, 6 patients had long-term dis-
ease control exceeding 2 years.10 The recommen-
ded dose of vorinostat for the phase IIb trial was
400 mg by mouth daily with dose reductions taken
for gastrointestinal or thrombocytopenia side ef-
fects. The most common drug-related AEs were
diarrhea (49%), fatigue (46%), nausea (43%),
anorexia (26%), and dysgeusia (24%); the most
common grade 3 or 4 AEs were thrombocytopenia
(5%), nausea (4%), anorexia (3%), and muscle
spasms (3%).
HDAC inhibitors have in general similar side effect
and safety profiles, but vorinostat given orally has
gastric side effects of diarrhea, nausea, and loss of
taste,which cancauseweight lossanddehydration,
especially in older patients. Other common symp-
tomsofHDAC inhibitors are fatigue and thrombocy-
topenia owing to platelet maturation arrest. The
initial warning of alterations in cardiac rhythm with
HDAC inhibitors was removed based on lack of ev-
idence. Elimination is primarily hepatic, with total
mean plasma clearance and elimination half-life of
1240 mL/min and 1.1 hours, respectively.26
Vorinostat has been combined with other
agents, especially with protease inhibitors and le-
nolidamide, in the setting of multiple myeloma.
With respect to CTCL, a single phase I safety
and efficacy multicenter clinical trial evaluated 23advanced MF/SS patients treated with vorinostat
(200, 300, and 400 mg/d) combined with bexaro-
tene (150, 225, and 300 mg/m2). Patients were al-
lowed to stay on treatment as long as their disease
was stable or improved. The maximum tolerated
dose for the therapies when combined were
determined to be vorinostat 200 mg/day plus
bexarotene 300 mg/m2 per day, lower doses
for vorinostat than standard monotherapy. A
confirmed objective responses was observed in
4 patients, unconfirmed response was observed
in 2 patients, and stable disease was observed in
15 patients.27 The most common treatment-
related AEs were hypothyroidism (35%), fatigue
(30%), and hypertriglyceridemia (30%). Five
drug-related serious AEs were reported in 4 pa-
tients (lymphangitis, lymph node abscess, skin ne-
crosis, gastroenteritis, and fall). Dose-limiting
toxicities experienced were grade 3 hypertrigly-
ceridemia and grade 1 diarrhea in patients taking
vorinostat 300 mg/d plus bexarotene 150 mg/m2,
and grade 3 neutropenia in patients taking vorino-
stat 400 mg/d plus bexarotene 225 mg/m2.27
The study was discontinued before meeting its
endpoints.ROMIDEPSIN (ISTODAR, DEPSIPEPTIDE,
FK228)
Romidepsin is a class I HDAC inhibitor with a
unique bicyclic structure with a central ester
bond. Unlike the more common synthetic benza-
mide compounds, cyclic compounds are found in
nature.28 For all of the T-cell lymphomas for which
it is approved, romidepsin is dosed at 14 mg/m2 as
a 4-hour intravenous infusion on days 1, 8, and 15
every 28 days.29 Potassium and magnesium are
recommended to be normal before infusion.
Romidepsin is the second HDAC inhibitor to be
approved by the FDA. In September 2009, romi-
depsin was approved for the treatment of CTCL
in patients who received at least 1 prior systemic
therapy. Similar global overall responses were
observed in 2 phase II open-label, multicenter clin-
ical trials conducted to evaluate clinical efficacy
and safety of romidepsin in patients with CTCLs
(specifically MF or SS)30,31 and accelerated
approval for PTCL.30–34 The global response rate
in the multicenter CTCL trial was 34%.30 This trial
used a global evaluation of the skin composed of
assessments of skin lesions by the modified skin
weighted assessment tool, lymph nodes, and
visceral compartments (by CT) and blood (by
flow cytometry), setting a new higher standard
for evaluation of CTCL patients’ response in clin-
ical trials.30,35 Approval was based not on overall
response, but on improvement in the duration
HDAC-Inhibitors for CTCL 761of response and pruritus over conventional
therapies. An ORR of 34% and CR rate of 6%
was also notable. Nausea, vomiting, fatigue, or
myelosuppression were the most commonly
encountered AEs. QT interval changes on electro-
cardiography that were insignificant clinically did
not correlate with decreased left ventricular ejec-
tion fraction, or elevated laboratory markers of
myocardial damage.36
Romidepsin was given accelerated approval for
patients with PTCLs who had received 1 or more
prior therapies. Approval was based on 2 single-
arm phase II studies. The first study included 45
patients with relapsed/refractory PTCL and a me-
dian of 3 prior therapies.31 The ORR of 38% (CR
18%) was achieved with a median duration of
response of 9 months.31 A second multinational
phase II study enrolled 130 patients with
relapsed/refractory PTCL and a median of 2
(range, 1–8) prior therapies. The primary endpoint
was the number of CRs or unconfirmed responses
assessed by independent review.29 The trial
achieved an ORR of 25% (CR or complete
response unspecified [CRU]) of 15%, with a me-
dian duration of response of 17 months.29 Of 19
patients with CR/CRUs, 17 (89%) had not experi-
enced disease progression at a median follow-up
of 13.4 months.29
The safety profile of romidepsin in patients with
PTCL is similar to patients with CTCL. The most
commonAEs inPTCLpatientswerenausea, fatigue,
and transient thrombocytopenia and granulocyto-
penia. In the pivotal PTCL trial, severe grade 3 or
higher AEs experienced bypatients included throm-
bocytopenia, neutropenia, and infections. The ORR
was 25% (33/130) with 15% of patients (19/130)
achieving a CR or unconfirmed CR.31 Based on
these trials, romidepsin was approved by the FDA
in 2011 for the treatment of PTCL in patients who
have received at least 1 prior therapy.29,31,36BELINOSTAT (BELEODAQ; PXD101
MECHANISM OF ACTION)
Belinostat [(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)
phenyl]prop-2-enamide] is a pan- HDAC inhibitor
with a sulfonamide-hydroxamide structure and
high affinity for the class I, II and IV HDACs.
In vitro, belinostat causes accumulation of
acetylated histones, restores expression of epige-
netically silenced tumor suppressor genes (trans-
forming growth factor b receptor II), represses
survivin (an antiapoptotic protein), and causes
cell-cycle arrest and apoptosis of malignant
cells.37 Belinostat is active at nanomolar concen-
trations (<250 nmol/L) and shows preferential
cytotoxicity toward malignant cells.Belinostat was granted orphan drug and accel-
erated designation in September 2014 by the
FDA for use in patients with relapsed or refractory
PTCL.38,39 Belinostat is included in the National
Comprehensive Cancer Network guidelines as
second-line therapy (category 2B) for patients
with relapsed PTCL.
A small, multicenter, phase II study was con-
ducted in 24 adults with relapsed/refractory
PTCL and 29 adults with MF/SS.39 Patients had
received a median of 3 and 4 prior systemic thera-
pies, respectively. PTCL patients’ prior treatments
included an autologous stem cell transplant in
21%; 40% and 55% of patients had stage IV dis-
ease, respectively. Belinostat was administered
at 1000 mg/m2 intravenously on days 1 through
5 every 3 weeks, with dose escalation to
1200 mg/m2 and 1400 mg/m2 permitted in cycles
2 and 3. The primary endpoint, overall response,
was 25% (8% CR) in PTCL patients. ORR in MF/
SS patients was 14% with 10% CRs and did not
meet the predetermined ORR needed to continue
the study. The median duration of response in the
2 groups was 109 and 83 days, respectively. AEs
were reported in 77% of patients included nausea
(62%), vomiting (26%), fever (21%), and dizziness
(21%).
A phase I study of patients with advanced he-
matologic malignancies enrolled 16 patients,
none of whom had MF or SS.19 Belinostat doses
were 600, 900, and 1000 mg/m2 per day given
by intravenous infusion. Phase I studies were con-
ducted to determine the optimal dose and route of
administration.26,40,41 The most common treat-
ment related AEs were nausea (50%), vomiting
(31%), fatigue (31%), and flushing (31%). Two pa-
tients with multiple myeloma experienced acute
renal injury from tumor lysis. Based on this study,
the dose of 1000 mg/m2 intravenously, days 1
through 5 of a 21- to 128-day cycle was selected
for subsequent phase II clinical trials. Studies
have investigated continuous dosing and oral
formulation; an optimal dose and schedule has
not yet been established.26,40
The phase II BELIEF study led to accelerated
approval of belinostat.40 This phase II multicenter
study was conducted at 62 sites enrolling 129
adults with relapsed/refractory PTCL and median
age of 64 years who had had a median of 2 prior
lines of therapies. All patients had received at least
one prior systemic treatment (96% CHOP or
CHOP-like regimens, including an autologous
stem cell transplant in 23%). Belinostat was
administered 1000 mg/m2 intravenously on days
1 through 5 every 3 weeks and was continued as
long as belinostat was effective and tolerated.
The primary endpoint, overall response, was
Duvic76226% with 11% CRs in 120 evaluable patients. The
median time to response was 5.6 weeks, but late
responses, beyond 6 months, were also seen. Re-
sponses were generally durable, with a median
duration of response of 8.4 months and 7.5% of
patients went on to receive a stem cell transplant.
Treatment was well-tolerated, with AE-related
discontinuation reported only in 7% of patients.
The most frequent grades III or IV AEs were throm-
bocytopenia (13%), neutropenia (13%), and ane-
mia (10%). In the BELIEF trial, QTc interval
prolongation was observed in 4% of patients and
grades 3 and 4 cytopenias in 10% to 15% of
patients.
After this accelerated approval, the FDA has
required the sponsor to conduct a dose-finding
trial of belinostat combined with CHOP (Bel-
CHOP), followed by a phase III trial of Bel-CHOP
versus CHOP as frontline treatment of PTCL. The
first study is currently active and recruiting patients
(NCT01839097), with the primary endpoint of
finding the maximum tolerated dose for belinostat
to be combined with CHOP. In this study, belino-
stat will be administered to 5 cohorts of patients
at 1000 mg/m2 on day 1, days 1 to 2, days 1 to
3, days 1 to 4, and days 1 to 5 of each 21-day
cycle.
Pharmacogenomic studies found reduced
UGT1A1 activity in individuals with the UGT1A1*28
polymorphism, which is most prevalent among
black individuals with 20% homozygosity. Thus,
dose reduction to 750 mg/m2 is recommended in
patients homozygous for UGT1A1*28 to minimize
toxicity.PANOBINOSTAT (LBH-589, FARYDAK)
Panobinostat is a potent and broad spectrum hy-
droxamic acid HDAC inhibitor that was recently
approved by the FDA in February 2015 for the
treatment of multiple myeloma. Panobinostat is
dosed orally 3 times weekly. CTCL patients with
SS had remarkable responses that were durable
in a phase I study conducted by Sharma and col-
leagues.42 The clinical trials for hematologic malig-
nancies including those involving patients with
CTCL were reviewed recently.43
A phase II, multicenter, open-label, clinical trial
was conducted in 79 MF/SS patients who had
formerly been treated with bexarotene and 60 bex-
arotene-naı¨ve patients.44 The dose was 20 mg
orally 3 days per week. The overall response by
the modified skin weighted assessment tool
assessment of skin involvement was only 17% in
all patients, 15.2% for bexarotene exposed, and
20% in the bexarotene-naı¨ve patients. The median
progression-free survival was 4.2 and 3.7 monthsin the bexarotene or no bexarotene groups,
respectively. The duration of response in the bex-
arotene exposed group was 5.6 months. Reduc-
tions of the modified skin weighted assessment
tool score were observed in 103 patients
(74.1%). The study design did not take into consid-
eration tumor flares so patients were taken off pre-
maturely for “progressive disease.”44 The most
common AEs were thrombocytopenia, diarrhea,
fatigue, and nausea. Thrombocytopenia and neu-
tropenia were the only grade 3 or 4 AEs in greater
than 5% of patients and were manageable.SUMMARY
Although romidepsin and vorinostat are the only
HDAC inhibitors currently approved for CTCL
(MF/SS), belinostat is also approved for PTCL.
Their efficacy and side effects were similar in the
pivotal trials. The overall response (OR) rate for
Vorinostat was 30% with no CRs and the OR
rate for romidepsin was 34% with a 6% CRS. Vor-
inostat has the advantage of oral administration,
but has more associated gastrointestinal side ef-
fects such as intolerable diarrhea and loss of taste
in some patients. Romidepsin can only be admin-
istered intravenously over 4 hours and has more
fatigue and nausea, which are the most frequent
reasons for stopping therapy. Thrombocytopenia
can occur with either and is dose related. QTc pro-
longation is a rare but potentially serious adverse
effect of the class, occurring in fewer than 5% of
patients treated. Romidepsin and vorinostat re-
sponders have continued therapy for over a year
with dose reductions taken in some cases for
toxicity or convenience.
There is little information regarding combina-
tions of HDAC inhibitors with other CTCL thera-
pies. Vorinostat added to electron beam therapy
did not increase the response rate or add to the
toxicity (Kim, unpublished, ASH abstract, 2014).
There are no data to exclude combining HDAC in-
hibitors with skin-directed therapies. Belinostat is
a new intravenous and Pabinostat a new oral
HDAC inhibitor approved for other indications
but in which phase II exploratory trials in CTCL pa-
tients have shown ORs of less than 20%.
Finally, although there are now several approved
treatments available for patients with advanced
MF/SS, the field is still in need of newer drugs
and approaches for this disease with poor
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